News

Evotec: Unusual alliance pays off
Enlarge image

BusinessGermany

Evotec: Unusual alliance pays off

10.07.2012 - Evotec has announced a license and collaboration agreement with Janssen Pharmaceuticals on a portfolio of small molecules and biologics.

The subsidiary of Johnson & Johnson targets a novel academic-biotech collaboration called CureBeta built around a portfolio of diabetes treatments in regenerative medicine put together in the lab of Harvard scientist Douglas Melton. The pharma pays a modest upfront of US$8m for the rights but promised to pay US$300m in milestones per programme. J&J receives the global exclusive rights to the programmes, which involve insulin-producing beta cells. Harvard and Evotec agreed to share profits. In the first stage of the collaboration, Harvard, the Howard Hughes Medical Institute and the Germanbiotech Evotec worked on new assays and tools for regenerating beta cells. With the help of J&J's research expertise, the partners hope to make all stages until approval. The appearance of a big pharma completes the alliance that comprised only academic researchers and a biotech company. "We have not only achieved our scientific goals of creating a superior beta cell drug discovery platform and generating a deep pipeline of novel and exciting targets, but we have also established a new model of collaboration between academia and industry that has proven highly efficient and effective in accelerating innovative scientific development," said Dr. Cord Dohrmann, the CSO at Evotec. Elmar Kraus, analyst at DZ Bank said: "Evotec promised and delivered a research and development alliance with one of the big players inthe field in the already huge and growing indication of diabetes. With this, the CureBeta initiative, established in 2011 with the Howard Hughes Medical Institute (HHMI) at Harvard has already paid off." Evotec shares rose 18% at the German Stock Exchange in Frankfurt.

M&AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn).

M&ASwitzerland

04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.

M&AFranceGermany

03.07.2014 Nicox S.A. is stretching beyond the European market: The French eye health specialist is set to acquire Aciex Therapeutics Inc., a US-based pharma company with several ophthalmic therapeutics nearing market maturity.

FinanceBelgium

01.07.2014 Belgian antibody specialist Ablynx has raised €41.7m through a private placement of new shares and plans on boosting their range of nanobodies in development.

BioeconomyBelgiumUK

30.06.2014 Building on a £1.2m financing round, Celtic Renewables partners with a Belgian pilot plant to bring its bio-fuel made from whisky production residue to an industrial scale.

ConventionEUUK

25.06.2014 Sun, celebrities and a scandal - the world’s largest biotech convention is getting off to an explosive start in San Diego, California.

InvestmentGermanyNetherlands

24.06.2014 Bayer Healthcare is getting back into gene therapy with a US$252m deal aimed at the development of a haemophilia A treatment.

InvestmentNetherlands

20.06.2014 Tomtom founder Pieter Geelen invests in Dutch biotech Ocello, the company behind a 3D mapping technology used for predicting drug behaviour in patients.

RegulatoryEU

17.06.2014 The member states of the European Union have agreed on a EU-wide directive for the authorisation process of genetically modified crops – with an opt-out for individual countries.

Events

All Events

Partner-Events

Vilnius (LT)

Life Sciences Baltics

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NOVACYT (F)4.99 EUR9.67%
  • CELLECTIS (F)14.00 EUR4.56%
  • PHARMING (NL)0.53 EUR3.92%

FLOP

  • PROSENSA (NL)10.48 USD-16.29%
  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%

TOP

  • SANTHERA (CH)72.55 CHF136.7%
  • CELLECTIS (F)14.00 EUR109.0%
  • ADDEX (CH)3.62 CHF62.3%

FLOP

  • THROMBOGENICS (B)8.78 EUR-51.2%
  • MERCK KGAA (D)64.18 EUR-50.1%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)72.55 CHF3564.1%
  • GW PHARMACEUTICALS (UK)432.00 GBP802.3%
  • PAION (D)2.92 EUR323.2%

FLOP

  • EVOCUTIS (UK)0.21 GBP-93.3%
  • CYTOS (CH)0.25 CHF-92.8%
  • THROMBOGENICS (B)8.78 EUR-72.8%

No liability assumed, Date: 09.07.2014